
FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma
The U.S. Food and Drug Administration (FDA) approved treatment with Monjuvi (tafasitamab-cxix) plus Revlimid (lenalidomide) and Rituxan (rituximab) for adults with relapsed or refractory follicular lymphoma. The effectiveness of Monjuvi was studied in the …